CAR-T Treatment: Determining the Survival Gain in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Clin Lymphoma Myeloma Leuk. 2020 Jul;20(7):490-491. doi: 10.1016/j.clml.2020.02.007. Epub 2020 Feb 19.

Authors

Andrea Messori¹, Vera Damuzzo², Luca Leonardi³, Laura Agnoletto³, Marco Chiumente³, Daniele Mengato³

Affiliations

¹ HTA Unit, Regional Health Service, Florence, Italy. Electronic address: andrea.messori.it@gmail.com.
² School of Hospital Pharmacy, Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
³ Scientific Direction, Italian Society for Clinical Pharmacy and Therapeutics, Milan, Italy.

PMID: 32173272
DOI: 10.1016/j.clml.2020.02.007

No abstract available

Publication types

Letter

MeSH terms

Humans
Lymphoma, Large B-Cell, Diffuse / mortality
Lymphoma, Large B-Cell, Diffuse / therapy*
Receptors, Chimeric Antigen / therapeutic use*

Substances

Receptors, Chimeric Antigen